Interestingly, similar concentrations of plasma in experiments with primary GMVECs did not cause significant cell death, indicating that CPF-containing plasma of patients with active FSGS is specifically damaging to podocytes (Figure 2b, right panel). The gene discussed is NR5A2; the disease is focal segmental glomerulosclerosis.